ProPhase Labs, Inc.

PRPH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $90.0K $678.0K $1.6M $9.1M $8.4M $6.8M $434.0K $1.6M
Accounts Receivable $1.5M $20.1M $35.8M $37.1M $37.7M $3.2M $2.0M $3.0M
Inventory $70.0K $1.1M $2.3M $4.0M $4.6M $3.0M $1.5M $1.9M
Total Current Assets $3.2M $30.6M $47.6M $60.8M $61.3M $15.9M $9.9M $18.2M
Property, Plant & Equipment $7.3M $5.9M $3.6M $2.3M $2.5M
Goodwill $4.0M $5.2M $5.2M $5.7M $5.7M $901.0K
Intangible Assets (Excl. Goodwill) $7.2M $9.8M $12.3M $8.5M $10.9M $1.2M
Total Assets $59.9M $63.2M $91.9M $87.6M $89.3M $31.4M $12.3M $20.7M
Liabilities
Accounts Payable $13.7M $8.6M $5.9M $7.0M $3.8M $432.0K $437.0K
Total Current Liabilities $53.1M $32.1M $20.9M $16.1M $15.5M $6.3M $933.0K $4.2M
Long-Term Debt $2.9M $0 $10.0M $10.0M
Total Liabilities $56.4M $55.8M $42.5M $24.0M $30.7M $20.8M $1.0M $4.2M
Stockholders' Equity
Retained Earnings $-73.1M $-58.4M $-5.0M $11.8M $2.6M $-3.6M $-1.5M $4.5M
Total Stockholders' Equity $3.5M $7.4M $49.4M $63.6M $58.6M $10.6M $11.2M $16.5M
← Newer Page 1 of 3 Older →